Sarcoidosis is a rare multisystem granulomatous disorder of unknown aetiology. The granulomas are inflammatory nodules full of macrophages. It is a multisystem disorder but commonly affects the lungs.
Demographics:
Age of onset 20-40
More common in females
More common in people of black ethnic origin
Skin features:
Erythema nodosum - nodules of inflamed subcutaneous fat on the shins
Lupus pernio - specific to sarcoidosis and presents with raisedpurple skin lesions, often on the cheeks and nose
Erythema nodosum presents as raised, red, tender, painful, subcutaneous nodules across both shins
Pulmonary manifestations:
Mediastinal lymphadenopathy
Pulmonary fibrosis
Pulmonary nodules
Symptoms can vary depending on which systems are affected:
Cough (dry)
SOB
Red or painful eyes
Swollen glands
Skin rashes
Pain in joints, muscles or bones
Numbness or weakness of the face, arms and legs
Systemic features:
Fever/night sweats
Fatigue
Weight loss
Liver manifestations:
Liver nodules
Cirrhosis
Cholestasis
Eye manifestations:
Uveitis
Conjunctivitis
Optic neuritis
Cardiac manifestations:
BBB
AV node block
Myocardial muscle involvement
Renal manifestations:
Stones - due to hypercalcaemia
Nephrocalcinosis
Interstitial nephritis
CNS manifestations:
Nodules
Pituitary involvement e.g. diabetes insipidus
Encephalopathy
PNS manifestations:
Facial nerve palsy
Mononeuritis multiplex
Bone manifestations:
Arthralgia (joint pain)
Arthritis
Myopathy
Lofgren's syndrome refers to a specific presentation of sarcoidosis with a classic triad of symptoms:
Erythema nodosum
Bilateral hilar lymphadenopathy
Polyarthralgia
Blood tests:
Raised angiotensin-converting enzyme (ACE)
Hypercalcaemia
Imaging:
CXR may show hilarlymphadenopathy
HRCT may show hilar lymphadenopathy and pulmonary nodules
MRI can show CNS involvement
PET scan can show active inflammation in affected areas
Histology:
Bronchoscopy with an US guided biopsy of mediastinal lymph nodes
Histology characteristically shows non-caseating granulomas with epithelioid cells
Management:
Conservative management considered in patients with no or mild symptoms
Oral steroids (6-24 months) are usually first line when treatment is required
Bisphosphonates protect against osteoporosis whilst on long-term steroids